Compare Stocks

→ “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARA Cara Therapeutics	$0.76 +4.1%	$0.83	$0.50 ▼ $4.67	$41.55M	0.74	598,080 shs	125,552 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARA Cara Therapeutics	+3.68%	-1.57%	-8.64%	+34.34%	-81.68%

Elon’s New Device is About to Shock the World (Ad)

Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”

Click here to see the details because there’s a lot of money at stake.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CARA Cara Therapeutics	3.6536 of 5 stars	3.4	1.0	0.0	4.2	0.9	1.7	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARA Cara Therapeutics	2.75	Moderate Buy	$9.75	1,182.73% Upside

Current Analyst Ratings

Latest ATL, CARA, GLOO, XAF, and TNI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2024	CARA Cara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
3/28/2024	CARA Cara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
3/6/2024	CARA Cara Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
3/5/2024	CARA Cara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARA Cara Therapeutics	$20.97M	1.98	N/A	N/A	$1.05 per share	0.72

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARA Cara Therapeutics	-$118.51M	-$2.18	N/A	N/A	N/A	-565.21%	-122.10%	-89.64%	5/13/2024 (Confirmed)

Latest ATL, CARA, GLOO, XAF, and TNI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2024	N/A	CARA Cara Therapeutics	-$0.38	N/A	+$0.38	N/A	N/A	N/A
3/4/2024	12/31/2023	CARA Cara Therapeutics	-$0.57	-$0.59	-$0.02	-$0.59	$2.34 million	$3.00 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARA Cara Therapeutics	N/A	4.54	4.43

Ownership

Institutional Ownership

Company	Institutional Ownership
CARA Cara Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
CARA Cara Therapeutics	4.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CARA Cara Therapeutics	55	54.67 million	52.37 million	Optionable

ATL, CARA, GLOO, XAF, and TNI Headlines

Source	Headline
	Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024 globenewswire.com - May 6 at 7:00 AM
	Secrets of the Stylish: Getting premiere ready with Robyn Cara harpersbazaar.com - May 2 at 10:03 PM
	Cara Maria Hatches a Revenge Plot on 'The Challenge: All Stars' Season 4 yahoo.com - May 2 at 10:03 PM
	Comedian Cara Connors on Coming Out, Being a “Sassy Gay Cowboy,” and Dating Gen Z msn.com - May 1 at 6:11 PM
	Time to Meander Through Cara Delevingne’s Dating History 😬 yahoo.com - April 30 at 4:27 PM
	Photos: Cara Delevingne and Luke Treadaway Enter Final Five Weeks in CABARET in London broadwayworld.com - April 29 at 10:00 PM
	Linn County hires Cara Matteson as new sustainability director thegazette.com - April 29 at 10:00 PM
	Neighbours' Remi and Cara caught out over Felix and JJ secret yahoo.com - April 29 at 11:59 AM
	Neighbours' Remi and Cara caught out over Felix secret digitalspy.com - April 29 at 6:57 AM
	Cara Delevingne's House Fire Cause Still A Mystery As LAFD Closes Investigation msn.com - April 28 at 5:44 PM
	Shaw: Cara Mund can win the primary inforum.com - April 27 at 8:36 PM
	Cara Porto-Osborn of Young + Wright Architectural bizjournals.com - April 26 at 2:33 PM
	Oruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical Officer finance.yahoo.com - April 24 at 4:37 PM
	KPRC 2 Athlete of the Week: Cara Pittman, Dawson Softball click2houston.com - April 20 at 1:55 PM
	Being the Marquette women's basketball coach means a lot to Cara Consuegra. She's ready to rebuild. usatoday.com - April 20 at 1:55 PM
	Port: Who is Cara Mund trying to please? inforum.com - April 20 at 1:55 PM
	Cara Therapeutics Inc money.usnews.com - April 18 at 7:13 PM
	The Challenge: Zach Nichols reacts to seeing Cara Maria Sorbello back for All Stars 4 msn.com - April 14 at 8:54 PM
	The Challenge’s Cara Maria Sorbello thought All Stars 4 castmates would reunite due to ‘hatred’ of her msn.com - April 14 at 8:54 PM
	NY GOP moves to knock ‘The Biggest Loser’ trainer Cara Castronuova out of Senate primary msn.com - April 14 at 8:54 PM
	Marshall Kaufman & Cara Stigger Discusses What Got Them into Law whas11.com - April 13 at 7:43 AM
	Buy Rating Affirmed for Cara Therapeutics: Promising Prospects for Oral Difelikefalin in Notalgia Paresthetica Treatment markets.businessinsider.com - April 12 at 10:51 PM
	Cara Therapeutics CMO sells shares worth over $2,000 investing.com - April 11 at 8:53 PM
	Buy Rating Affirmed for Cara Therapeutics Amidst Promising Korsuva Ph 2/3 Program and Market Potential markets.businessinsider.com - April 10 at 5:39 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cara Therapeutics

NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial